Abbisko Cayman (HKG:2256) plans to spend up to HK$200 million to buy back its shares on-market, a Monday bourse filing said.
The drugmaker was authorized to repurchase a maximum of 70,219,935 shares, representing up to 10% of its issued shares as of June 18, 2024.
The buyback will be financed through the company's financial resources.
The oncology therapies developer also plans to grant its board a new repurchase mandate at its upcoming 2025 annual general meeting.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。